Substitute for Form 144	9 A & B/PTO		
		DISCULOUPE F	
		DISCLOSURE E Y APPLICANT	TO TO
			. Bni
(use	as many shee	ets as necessary) FEB 1821	160
Sheet	<del></del>	of &	NEW S

	1410D11 1ED F 10/3B/06 A & B (06-03)
Сотр	olete if Known
Application Number	10/519,990
Confirmation Number	3209
Filing Date	January 04, 2005
First Named Inventor	Nicoletta BIANCHI
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q85654

			U.S. I	PATENT DOCUM	ENTS
Examiner	Cite	Document	Number	Publication Date	
Initials*			Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
		US			

			F	OREIGN PA	TENT DOCUMEN	NTS .	
Examiner Cite		Foreign Patent Document		Publication Date	Name of Patentee or		
Initials* No.1	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation*

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.							
SG		G. RODGERS et al.," Novel Treatment Options in the Severe β-Globin Disorders", British Journal of Haematology, 91:263-268, 1995.							
		J. ROCHETTE et al. "Fetal Hemoglobin Levels in Adults", Blood Reviews, 8:213-224, 1994.							
•••		N. BIANCHI et al., "Accumulation of γ-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine", British Journal of Haematology, 113(4): 951-961; 2001							
4'		DOVER et al, "Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate", New England Journal of Medicine, 327:569-570, 1992.							
		IKUTA et al. "Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Expression and Hematopoiesis" Annals of New York Academy of Sciences, 850: 87-99, 1998							
		KAHAN, "Sirolimus: a comprehensive review" Expert Opinion. 2001 Nov; 2(11): 1903-1917	1						
		DICKMAN et al. "Antifungal Rapamycin Analogues with Reduced Immunosuppressive Activity", Biiorganic & Medicinal Chemistry Letters 10(2000) 1405-1408							
		DELL, "Antiproliferative Naphthopyrans: Biological Activity, Mechanistic Studies and Therapeutic Potential", Current Medicinal Chemistry, 1998, 5: 179-194							
~		TRAUTMANN, et al. "Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis". Journal of Allergy Clinical Immunology, November 2001 839-846							
		REITAMO et al. "Efficacy of Sirolimus (rapamycin) administered concomitantly with a sub therapeutic dose of cyclosporine in the treatment of severe psoriasis: a randomized controlled trial" British Journal of Dermatology, 2001: 145: 438-445.							
<i>)</i> ·		GUBA et al. "Rapamycin inhibits primary and metastasis tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor" National Medical February 2002, Vol. 8, No. 2, 128-135							
		GARBER "Rapamycin's Resurrection: A new way to target the cancer cell cycle" National Cancer Institute, 2001, Vol. 93, No. 20, 1517-1519							
		BENITO et al. "Sirolimus (Rapamycin) for the treatment of refractory acute graft-versus-host disease", Transplantation, Vol. 72, No. 12, December 27, 2001, 1924-1929							
		RADOVANCEVIC et al. "Rapamycin reduces rejection in heart transplant recipients" Transplantation Proceedings, Vol. 33, 3321-3222, 2001							
		NISHIDA et al. "Sirolimus (Rapamycin)-Based Rescue Treatment following chronic rejection after liver transplantation" Transplantation Proceedings, 33: 1495 (2001)							
		BIANCHI et al. "Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs" Biochemical Pharmacology Vol. 60, 31-40, 2000							
SG		BIANCHI et al. "The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells". British Journal of Haematology, 1999 104:258-265							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

		·· · · · · · · · · · · · · · · · · · ·
SG	FIBACH, "Techniques for Studying Stimulation of Fetal Hemoglobin Production in Human Erythroid Cultures", Hemoglobin, 22(5&^), 445-458, 1998	
	FIBACH et al. "Hydroxyurea Increases Fetal Hemoglobin in Cultured Erythroid Cells Derived From Normal Individuals and Patients with Sickle Cell Anemia or β-Thalassemia" Blood, Vol. 81, No. 6 (March 15), 1993:1630-1963.	
	HEID et al. "Real Time Quantitative PCR", Genome Research, 6:986-994, 1996	
SG	GIBSON et al. "A Novel Method for Real Time Quantitative RT-PCR", Genome Research, 6:995-1001, 1996	

		1	I
Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/29/2007



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

THE DOOL BOTTON O

FILE	12 N8C U PU1/P10			
	MODIFIED PTO			
	1	4 0	$\Lambda\Lambda$	7

Substitute for Form 14	bstitute for Form 1449 A & B/PTO		€0mp	plete if Knowlu / 51999	
• )				Application Number	Not Yet Assigned
INFO	RMATION	DISCLOS	ÜRE	Confirmation Number	Not Yet Assigned
	STATEMENT BY APPLICANT			Filing Date	January 04, 2005
<u> </u>			<del></del>	First Named Inventor	Nicoletta BIANCHI et al
(us	e as many sheet	s as necessar	ry)	Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	Q85654

			U.S.	PATENT DOCUM	ENTS
		Document N	umber		
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			
		2U			
		US		1	

·			F	OREIGN PA	TENT DOCUMEN	its	
Examiner	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	Translation <sup>6</sup>
Initials* No.1		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	I ranslation
SG		wo	0168147	Α	09-20-2001		
						·	
	·						

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
SG		JOHNSON JULIE ET AL.: "Treatment of beth-thalassemia in the mouse by regulated expression of AAV-encoded erythropoietin" BLOOD, vol. 98, no. 11 part 2, November 16, 2001, page 410b XP009023880	
SG		43 <sup>rd</sup> Annual Meeting of the American Society of Hematology. Part 2; Orlando, Florida< USA; December 07-11, 2001 ISSN: 0006-4971	
SG		WO 0168147 A BIANCHI NICOLETTA; FERIOTTO GIORDANA(IT); GAMBARI ROBERTO (IT); m) September 20, 2001 Page 1, Paragraph 1-3, Page 5, Paragraph 1	
			-

Examiner Signature	/Satyanarayan Gudibande/	Date Considered	01/29/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.